Yuriko Nagane

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, Kimiaki Utsugisawa, Michael Benatar et al. · The Lancet Neurology · 2017 · 745 citations

Multicentre Study, Pharmacology, Medicine +3

Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study

Vera Bril, Artur Drużdż, Julian Großkreutz et al. · The Lancet Neurology · 2023 · 227 citations

Clinical Trials, Generalised Myasthenia Gravis, Pharmacotherapy +3

Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study

James F. Howard, Saskia Bresch, Angela Genge et al. · The Lancet Neurology · 2023 · 213 citations

Medicine, Surgery, Clinical Trials +1

Reduction with age in methylcytosine in the promoter region −224∼−101 of the amyloid precursor protein gene in autopsy human cortex

Hideo Tohgi, Kimiaki Utsugisawa, Yuriko Nagane et al. · Molecular Brain Research · 1999 · 180 citations

Neurodegenerative Diseases, Alzheimer's Disease, Autopsy Human Cortex +9

International clinimetric evaluation of the MG‐QOL15, resulting in slight revision and subsequent validation of the MG‐QOL15r

Ted M. Burns, Reza Sadjadi, Kimiaki Utsugisawa et al. · Muscle & Nerve · 2016 · 144 citations